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Abstract Upfront autologous stem cell transplantation
(ASCT) is the standard therapy for younger multiple myeloma
(MM) patients. MM patients usually undergo stem cell mobi-
lization with cyclophosphamide (CY) followed by granulo-
cyte colony-stimulating factor (G-CSF), or with G-CSF alone.
A limited number of randomized studies are available com-
paring costs of different mobilization strategies. Eighty
transplant-eligible patients aged up to 70 years with untreated
MM were included in this prospective study. The patients
were treated with RVD induction for three 21-day cycles and
randomized 1:1 at inclusion into one of the two mobilization
arms CY 2 g/m2 + G-CSF [arm A] vs. G-CSF alone [arm B].
Plerixafor was given according to a specific algorithm if
needed. Sixty-nine patients who receivedmobilization follow-
ed by blood graft collection were included in the cost analysis.
The median total costs of the mobilization phase were signif-
icantly higher in arm A than in arm B (3855 € vs. 772 €, p ≤
0.001). The cumulative median cost of the mobilization and
collection phases was significantly lower in arm B than in arm
A (8524 € vs. 11,622 €, p = 0.012). There was no significant
difference between the arms in the total median costs of ASCT
(n = 59) (34,997 € in arm Avs. 31,981 € in arm B, p = 0.118).
Mobilization with G-CSF alone seems to be a preferable mo-
bilization method for MM patients in terms of mobilization
and apheresis costs. In addition, it requires less hospital re-
source utilization.
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Introduction
Autologous stem cell transplantation (ASCT) is a standard
therapy in symptomatic younger multiple myeloma (MM) pa-
tients [1, 2]. ASCT has been shown to improve overall sur-
vival (OS), event-free survival (EFS), and complete remission
(CR) rates when compared with standard therapy [3, 4].
Currently, upfront ASCT is recommended for all transplant-
eligible patients, in spite of the introduction of novel myeloma
drugs (e.g., proteasome inhibitors and immunomodulatory
drugs) [5]. In addition, ASCT has been shown to be an effec-
tive treatment strategy for relapsed disease, even for patients
with prior ASCT [6, 7]. Because almost all ASCTs in adults
are performed using blood stem cell grafts [8], successful stem
cell mobilization and collection are prerequisites for ASCT.
However, the optimal mobilization regimen is still under
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debate and mobilization strategies differ between various cen-
ters and countries.
Traditionally, stem cell mobilization in myeloma patients
has been achieved with high-dose cyclophosphamide (CY)
(4–7 g/m2) followed by granulocyte colony-stimulating factor
(G-CSF) [9, 10]. More recently, lower doses of CY (1.5–2 g/
m2) combined with G-CSF have been used [11, 12]. However,
due to the toxicity of cyclophosphamide, mobilization with G-
CSF alone has become a preferred method for stem
cellmobilization in many transplantation centers [13, 14].
This concept has been supported by recent studies showing
that the use of cyclophosphamide-basedmobilization does not
have an impact on disease control or survival after ASCT
[15–17].
Stem cell mobilization with G-CSF alone has become a
more feasible option because of the introduction of plerixafor
(CXCR4 antagonist, Mozobil®). The superiority of G-CSF
plus plerixafor over G-CSF alone has been shown in a phase
III study [18]. While plerixafor is generally well tolerated and
is associated with a robust stem cell mobilization, cost is the
major factor limiting its use. The official hospital price for a
single 24 mg plerixafor dose in Finland is 6250 €. Many
algorithms to rationalize plerixafor use have been published
[19, 20]. However, there are only a few algorithms based on
prospective data and/or prospective validation with cost-
effectiveness analysis [21].
As a part of a mobilization substudy of the Finnish
Myeloma Study Group-MM02 prospective phase II trial
(#NCT01790737), we have evaluated the costs of different
phases (mobilization, stem cell collection, high-dose therapy,
and early post-transplant) of ASCT in MM patients who
underwent mobilization with low-dose CY plus G-CSF vs.
with G-CSF alone after lenalidomide-based induction
(lenalidomide, bortezomib, and dexamethasone, RVD).
Patients and methods
Patients
Eighty transplant-eligible patients aged up to 70 years with
untreated MM were included in this prospective phase II
study. The main exclusion criteria were peripheral neuropathy
grade ≥2, significant liver dysfunction, severe cardiac dys-
function, severe renal failure (glomerular filtration rate
<15 ml/min, unless in hemodialysis) and contraindication for
the use of thromboprophylaxis or a history of active malig-
nancy during the past 5 years [22].
Sixty-nine patients (34 patients in arm A and 35 patients in
arm B) from whom CD34+ cells were successfully collected
were included in this cost analysis. Eleven patients (14 %)
were dropped out before mobilization therapy due to toxicity
(n = 9) or early progression (n = 2). Of the collected patients,
10 (14 %) patients who underwent mobilization did not pro-
ceed to autologous transplantation due to progressive disease
(n = 6), allogeneic transplantation (n = 3), or severe comorbid-
ities (n = 1). There were no mobilization failures. The patient
characteristics of the mobilization study are presented in
Table 1. There were no significant differences between the
groups in terms of median levels of hemoglobin, leukocyte,
platelet, albumin, creatinine, or β2-microglobulin prior to mo-
bilization therapy or high-dose treatment and ASCT (data not
shown).
Treatment and mobilization
The patients were randomized (1:1) at inclusion into one of
the two mobilization arms and treated with RVD induction for
three 21-day cycles [22]. The mobilization in arm Awas CY
2 g/m2 on d + 1 plus filgrastim 5 μg/kg/day starting on d + 4
and in arm B, filgrastim 10 μg/kg/day alone starting on d + 1.
In arm A, patients were hospitalized for CY and mesna infu-
sions and the median length of stay was 3 days. Plerixafor was
given subcutaneously with a dose of 240 μg/kg if the B-
CD34+ level was <10 × 106/L in either arm provided that the
white blood cell count was at least 10 × 109/L in arm A or d +
5 has been achieved in arm B. Plerixafor was also given if the
yield of the first apheresis was <1 × 106/kg CD34+ cells. If
plerixafor was started, it was continued until the
predetermined number of CD34+ cells were collected.
Apheresis was initiated if the blood CD34+ cell level was
>10 × 106/L on d + 10 or on d + 5 in arms A and B, respec-
tively. The collection target was defined beforehand (≥3 × 106/
kg CD34+ cells for a single transplant or ≥6 × 106/kg if two
transplants were an option). High-dose melphalan (200 mg/
m2) was used as high-dose therapy and G-CSF was recom-
mended after the graft infusion starting on d + 5 if the number
of collected CD34+ cells was <3 × 106/kg [22].
Financial analysis
The costs per inpatient day were collected from all participat-
ing transplantation units (five university hospitals in Finland).
The costs of routine treatments (e.g., antibiotics, intravenous
fluids) and procedures (e.g., mandatory laboratory tests) dur-
ing hospital stays were included in the costs of the inpatient
day. Because there were some differences between the hospi-
tals, the average values of the costs were calculated and were
used in the cost calculations. The prices of medications were
acquired from the Hospital Pharmacy of Kuopio University
Hospital, Kuopio, Finland, and these prices were used for all
patients because prices are generally the same in all Finnish
hospitals. All blood products were supplied by The Finnish
Red Cross Blood Service, and the prices of the products used
were as published on their Web site. Unscheduled hospital
stays (e.g., due to adverse events of mobilization therapy)
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were noted in the calculations when present. The costs of
high-dose treatment and early post-transplant phase were cal-
culated for transplanted patients. The estimated average costs
used in the calculations are presented in Table 2.
Statistics
All calculations and statistical analyses were conducted using
IBM SPSS Statistics 23.0 for Windows (IBM Corp., Armonk,
NY, USA). Due to a low number of observations, Fisher’s
exact test, the Mann–Whitney U test, and Pearson’s chi-
squared test were used to analyze the data. Continuous vari-
ables are presented as medians with ranges and categorical
variables in percentages. A two-tailed p value of less than
0.05 was considered statistically significant.
Ethics
The Research Ethics Committee of the Northern Savo
Hospital District approved the study protocol, and it was con-
ducted according to the Declaration of Helsinki, International
Conference of Harmonization and Guidelines for Good
Clinical Practice.Written informed consent was obtained from
Table 2 Estimated average costs
Phase/cost Amount/price €
General costs
Inpatient/hospital day (incl. routine treatments) 1000
Platelets (Bsingle unit/bag^) 454
Red blood cells (Bsingle unit/bag^) 142
Mobilization phase
Cyclophosphamide (2 g/m2) +mesna 195
G-CSF
• 30 MU (outpatient/inpatient) 70/11
• 48 MU (outpatient/inpatient) 110/15
Plerixafor (Mozobil®) 24 mg 6250
Collection phase
Measurement of circulating CD34+ cells 150
Apheresis (incl. all material and laboratory costs) 2226
G-CSF granulocyte colony-stimulating factor, MU million units
Table 1 Patient characteristics
Variable Arm A (CY+G-CSF),
n = 34
Arm B (G-CSF),
n = 35
Significance
p
Sex, n (%) 1.000
Men 18 (53 %) 19 (54 %)
Women 16 (47 %) 16 (46 %)
Age (years) 0.828
Median (range) 62 (48–69) 62 (40–70)
Weight (kg) 0.674
Median (range) 76 (48–108) 74 (51–117)
ISS, n (%) 0.438
I 6 (17 %) 13 (37 %)
II 23 (68 %) 15 (43 %)
III 5 (15 %) 7 (20 %)
IMWG risk, n (%) 0.160
Low 5 (15 %) 3 (9 %)
Standard 26 (76 %) 25 (71 %)
High 3 (9 %) 7 (20 %)
Disease status, prior to mobilization, n (%) 0.645
VGPR or better 20 (59 %) 18 (51 %)
PR 12 (35 %) 16 (46 %)
SD 1 (3 %) –
PD 1 (3 %) 1 (3 %)
Collection target 0.469
For single transplantation (≥3 × 106/kg
CD34+ cells)
13 (38 %) 17 (49 %)
For two transplantations (≥6 × 106/kg
CD34+ cells)
21 (62 %) 18 (51 %)
CY cyclophosphamide, G-CSF granulocyte colony-stimulating factor, ISS International Staging System, IMWG
InternationalMyelomaWorking Group, VGPR very good partial response, PR partial response, SD stable disease,
PD progressive disease
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all patients before inclusion. The Finnish Myeloma Study
Group-MM02 trial was approved by the Finnish Medicines
Agency and registered at www.clinicaltrials.gov as
#NCT01790737.
Results
The median number of aphereses was two (range 1–3 in arm
A and 1–4 in arm B) in both arms (p = 0.273). The proportion
of patients reaching the predetermined number of CD34+ cells
with one to two aphereses was 62% in armA and 50% in arm
B (p = 0.662). All patients in both arms reached a yield of
≥2 × 106/kg CD34+ cells with ≤3 aphereses. The total stem
cell yield was 6.7 × 106/kg CD34+ cells (range 2.2–12.4 ×
106/kg) in arm A and 5.3 × 106/kg CD34+ cells (2.4–12.4 ×
106/kg) in arm B (p = 0.012). The median number of the stem
cell storage bags was significantly lower (p = 0.013) in arm A
than in arm B (4; range 2–8 vs. 5; 2–12). The detailed results
of a mobilization substudy of the Finnish Myeloma Study
Group-MM02 trial have been presented elsewhere [22].
The median total costs of the mobilization phase were sig-
nificantly higher (p ≤ 0.001) in arm A than in arm B (3855 €;
range 2615 €–16,400 € vs. 772 €; 560 €–13,126 €). This was
mostly due to the hospital treatment period needed for cyclo-
phosphamide mobilization. The median costs of G-CSF were
significantly higher (p ≤ 0.001) in arm B than in arm A (747 €;
560 €–1000 € vs. 660 €; 420 €–960 €). There were four (12%)
hospital treatment periods due to fever in arm A after mobili-
zation therapy vs. one (3 %) in arm B (p = 0.169).
The median total costs of the collection phase were 7752 €
(range 3376 €–13,376 € [armA], 3376 €–14,504 € [arm B]) in
both arms (p = 0.814). The cumulative median costs of the
mobilization and the collection phases of all patients was
11,622 € (5991 €–28,678 €) in arm A and 8524 € (3936 €–
27,630 €) in arm B (p = 0.012). Among the patients requiring
only one or two aphereses, the cumulative median costs of the
mobilization and the collection phases were significantly low-
er in arm B than in arm A (5316 €; 3936 €–12,186 € vs. 8694
€; 5991 €–16,991 €, p ≤ 0.001) and (8524 €; 7498 €–14,584 €
vs. 12,620 €; 10,378 €–26,617 €, p ≤ 0.001), respectively. In
this patient group, three patients (6 %) were treated with
plerixafor. There was no significant difference in the cumula-
tive median costs of the mobilization, and the collection
phases in patients requiring three or more aphereses as the
median cost was 15,013 € (13,765 €–28,678 €) in arm A
and 14,097 € (10,900 €–27,630 €) in arm B (p = 0.460).
Altogether, seven patients (10 %) (two patients in arm A and
five patients in arm B, p = 0.428) were treated with plerixafor.
Only two patients (3 %, a single patient in both arms) were
treated with plerixafor before the initiation of apheresis. Five
patients (7 %) were treated with plerixafor before the second
(n = 4, 6 %) and/or third (n = 4, 6 %) apheresis sessions. In
addition, a single patient (1 %) received plerixafor before the
fourth apheresis session. Of note, 22 % of all patients (13 % in
arm A and 30 % in arm B) requiring three or more aphereses
were treated with plerixafor (p = 0.588). Among the patients
with the same predefined collection target, the cumulative
median costs of the mobilization and the collection phases
were comparable between the arms (for single transplantation,
arm A 8991 €; 5991 €–16,991 € vs. arm B 8494 €; 3936 €–
14,585 €, p = 0.103 and for two transplantations, 13,622 €;
7231 €–28,678 € vs. 8980 €; 3936 €–27,630 €, respectively,
p = 0.140).
The median cost of high-dose therapy and the early post-
transplant phase was 22,829 € (16,340 €–77,585 €) in arm A
and 22,183 € (15,829 €–30,375 €) in arm B (p = 0.785). The
total median cost of stem cell mobilization, collection, and
transplantation was 34,997 € (23,366 €–82,366 €) and
31,981 € (22,871 €–53,067 €) in arms A and B, respectively
(p = 0.118). The detailed costs of different phases are present-
ed in Table 3.
Discussion
The vast majority of all studies concerning cost-
effectiveness of different mobilization strategies have
been retrospective [23–29]. Although many of these
studies investigate well-matched historical cohorts, their
retrospective design without randomization makes gen-
eralization of their results difficult. In addition, because
the majority of published pharmacoeconomic studies are
from the USA and healthcare systems vary greatly from
country to country, the results cannot be directly gener-
alized to other countries.
The most comprehensive prospective data available are
from an interim analysis of an Italian study by Milone
et al. The recruited MM patients were compared with a
bias-adjusted, historical control group. All patients
underwent mobilization with chemomobilization + G-
CSF, and plerixafor was given according to a specific
algorithm (Bon-demand^). The main finding of the cost-
effectiveness analysis in this study was that the on-
demand strategy did not result in an increase in overall
costs [21]. In another prospective study from the UK (the
PHANTASTIC trial), the routine use of plerixafor with G-
CSF mobilization therapy resulted in an average cost in-
crease of £5245 per MM patient [30]. In our study, mo-
bilization with G-CSF combined with preemptively ad-
ministered plerixafor resulted in significantly lower total
costs of mobilization and collection in patients requiring
only one or two aphereses when compared with mobiliza-
tion with CY + G-CSF. Thus, G-CSF alone seems to be a
preferable and adequate method for stem cell mobilization
in the majority of MM patients. Because mobilization
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with CY + G-CSF usually results in a higher stem cell
yield, it might be justified for MM patients who are in a
high-risk group for poor mobilization. Stratification of
mobilization therapy by clinical characteristics that are
identifiable before initiation of mobilization, however,
has been reported to be problematic [31]. It might also
be useful when stem cells are collected for multiple trans-
plantations or when the collection target is set high for
any reason. In the consensus guidelines mobilization with
G-CSF alone is categorized as an option for first-line mo-
bilization for MM patients, but it should be limited to
patients with no more than one previous line of therapy,
not previously treated with melphalan or >4 cycles of
lenalidomide [19]. Preemptive plerixafor may be used in
patients with inadequate mobilization.
We have previously reported on changes in CD34+ stem
cell subclasses and lymphocyte subsets of grafts after different
mobilization therapies in myeloma patients [32]. These pre-
liminary observations have been confirmed in a recent
substudy of the Finnish Myeloma Study Group-MM02 trial
[33]. In that study, patients mobilized with G-CSF had a great-
er proportion of primitive stem cells andmuch higher numbers
of lymphocytes and natural killer cells in their grafts compared
with the grafts of patients mobilized with CY + G-CSF.
Whether these changes in the graft composition have an im-
pact on progression-free survival or overall survival after
ASCT is still an open question and longer follow-up is neces-
sary to address it.
In this study, the median number of the stem cell storage
bags was significantly higher among patients mobilized with
G-CSF alone. This is probably due to fact that CD34+ cell/
mononuclear cell (MNC) ratio is lower in G-CSF mobilized
apheresis products. As the grafts are stored at standard cell
concentrations, this leads to a higher number of storage bags.
It is notable that the Finnish Myeloma Study Group-MM02
study protocol did not include standardization of graft preser-
vation. It is therefore possible that there might have been dif-
ferences in stem cell storage concentration between the partic-
ipating transplantation centers. The difference between mobi-
lization methods in the number of the stem cell storage bags,
however, was small and its possible impact on the total costs is
likely to be only modest. The number of plerixafor-treated
patients in this study was too low for any statistical
subanalysis on this matter but the use of plerixafor with G-
CSF mobilization have been reported to result in a greater
number of storage bags [34].
In conclusion, mobilization with G-CSF results in lower
total costs of mobilization and collection than mobilization
with CY +G-CSF in patients requiring only one or two aphe-
reses. In patients requiring three or more aphereses, there were
no significant differences in the costs of the two mobilization
approaches. The total costs of ASCT were comparable
Table 3 Median costs
Phase/cost median ArmA (CY +G-CSF),
(€)
Arm B (G-CSF),
(€)
Significance
p
Mobilization phase (n = 69)
CY (2 g/m2) + mesna (Uromitexan®) 195 0 <0.001
G-CSF 660 747 <0.001
Plerixafor (Mozobil®) 0 0 0.281
Treatment period (hospital days) 3000 0 <0.001
Total (mobilization) 3855 772 <0.001
Collection phase (n = 69)
Measurements of circulating CD34+ cells 300 300 0.925
Aphereses 4452 4452 0.273
Treatment period (hospital days) 3000 3000 0.228
Total (collection) 7752 7752 0.814
High-dose treatment and early post-transplant phase (n = 59)
Melphalan 1375 1375 1.000
Red cell transfusions 0 0 0.300
Platelet transfusions 908 908 0.722
Post-transplant G-CSF 0 0 0.431
Treatment period (hospital days) 21,000 19,500 0.795
Total (high-dose treatment and early post-
transplant)
22,829 22,183 0.785
Total costs (n = 59) 34,997 31,981 0.118
CY cyclophosphamide, G-CSF granulocyte colony-stimulating factor
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between the arms. Because there are no data available from
prospective studies regarding stratification of mobilization
therapy for different risk groups, such as patients with high
risk of poor mobilization or early disease progression after
ASCT, future studies including also cost-effectiveness analy-
ses concerning these aspects are warranted to improve selec-
tion of an optimal mobilization therapy for individual patients.
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